1. P812: LONG-TERM COMPLEMENT INHIBITION AND SURVIVAL OUTCOMES IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: AN INTERIM ANALYSIS OF THE RAVULIZUMAB CLINICAL TRIALS. (23rd June 2022) Authors: Kulasekararaj, A.; Brodsky, R.; Griffin, M.; Kulagin, A.; Ogawa, M.; Wang, J.; Mujeebuddin, A.; Nishimura, J.-I.; Peffault de Latour, R.; Szer, J.; Lee, J. W. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 706 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗